EN DE
Watch Precision Biosensor Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Precision Biosensor Inc. (335810) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Precision Biosensor Inc. stock KRW 1,415, price KRW 1,355, upside +4.5%, quality 37 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

PB Precision Biosensor Inc. logo Thin data Nov 10, 2026

Precision Biosensor Inc.

335810 · KQ
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Low debt
Revenue last quarter +27% vs. a year ago.
Fair value 1,415 KRW · Fairly valued
Expensive Growth (revenue 5y +18.1 %/yr in KRW)
Mixed vs. peers (5/10)
Quality 37/100
Loss-making · -26.9% net margin (TTM)
Negative free cash flow
Narrow moat 12/100
Thin data
Estimate
Watch Precision Biosensor Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

17,600 KRW 1,190 KRW Fair Value 1,415 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 1,190 KRW – 17,600 KRW · fair‑value band 1,062 KRW – 1,769 KRW · the 1,355 KRW price screens below the 1,415 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Precision Biosensor in your weekly email

Every Wednesday you see whether Precision Biosensor is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Precision Biosensor, Inc. engages in the development, production, and sale of immune diagnostic kits in South Korea. It offers Exdia TRF Plus, an immunodiagnosis POCT platform; and Exdia PT10 and Exdia PT10S, a clinical chemistry POCT platform.

Show moreShow less

The company was founded in 2009 and is headquartered in Daejeon, South Korea.

Stock analysis

Precision Biosensor Inc. (335810) currently trades at 1,355 KRW, while our estimate is 1,415 KRW, so the stock looks roughly fairly valued today (gap 4.3%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 1,062 KRW (bear) to 1,769 KRW (bull), the price of 1,355 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Precision Biosensor Inc. reported revenue of 19.9B KRW in FY2025 versus 15.9B KRW in FY2021, a compound +5.8%/yr. Reported net income was −10.0B KRW in FY2025.

Key figures

Market cap 29.6B KRW (≈ $22.2M) Micro · P/S ratio 1.33 · EPS (TTM) −290.33 KRW · Net margin −26.9% · Return on equity −20.2% · Return on assets (EBIT) −8.3% (5-year average) · Operating margin −19.5% · Revenue (TTM) 23.7B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 57% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at 4%, 335810 screens richer than that median.

Fair Value

Bear 1,062 KRW Fair Value 1,415 KRW Bull 1,769 KRW
Price 1,355 KRW · Upside +4.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 8
How much profit the company makes from its sales and capital
Quality Growth 27
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 49
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 60
How calm the share price moves, does not count
Price momentum 17
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 4
Distance to the 52-week high, does not count
New shares 78
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+4.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.1%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−16.9% (2020) → −27.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 335810, get fair value alerts →

Compare Precision Biosensor Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 37 · Below median
Fair Value upside +4.5% · Above median
Profitability
Return on assets −18.9% · Below median
Net margin (12 months) −26.9% · Bottom 25%
Operating margin (12 months) −19.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 26.9% · Top 25%
Balance sheet
Debt / equity 0.05× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.90× · Cheapest 25%
P/S (12 months) 1.25× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)39 · sector 17
FUTURE (revenue growth)100 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)98 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs 335810
DexCom, Inc DXCM $79.92 $89.18 +12% vs 335810
Stryker Corporation SYK $324.29 $358.30 +10% vs 335810
STERIS plc STE $257.12 $279.53 +9% vs 335810
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs 335810
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs 335810
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs 335810
Abbott Laboratories, ABT $110.46 $75.28 −32% vs 335810
Medtronic plc MDT $101.59 $65.61 −35% vs 335810
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs 335810

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Precision Biosensor Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Precision Biosensor Inc. Fair Value". https://www.fairvalue-calculator.com/stock/335810

Frequently asked questions

Is Precision Biosensor Inc. (335810) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 1,415 KRW versus a price of 1,355 KRW, about +4% upside (fairly valued).
What is the fair value of 335810?
Our estimate for Precision Biosensor Inc. is 1,415 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 1,355 KRW.
What is the quality score of 335810?
Precision Biosensor Inc. has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Precision Biosensor Inc. (335810)?
Our calculated price target is the estimate of 1,415 KRW (as of Nov 10, 2026). Cautious scenario 1,062 KRW, optimistic scenario 1,769 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Precision Biosensor Inc. stock forecast for 2026?
Our estimate puts fair value at 1,415 KRW, about +4% upside versus a price of 1,355 KRW (fairly valued). Cautious scenario 1,062 KRW, optimistic scenario 1,769 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Precision Biosensor Inc. (335810)?
Precision Biosensor Inc. reported trailing-twelve-month revenue of about 23.7B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Precision Biosensor Inc. (335810)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Precision Biosensor Inc. it is 1,415 KRW per share (as of Nov 10, 2026), against a price of 1,355 KRW.
Is Precision Biosensor Inc. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 335810 trades below its calculated fair value: price 1,355 KRW, fair value 1,415 KRW, a gap of about +4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 335810?
No. The price is what the market pays today (1,355 KRW); the fair value is what the company's own numbers justify (1,415 KRW). For Precision Biosensor Inc. the two are 60.34 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Precision Biosensor Inc. worth?
The market values Precision Biosensor Inc. at about 29.6B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 1,355 KRW; our models calculate a fair value of 1,415 KRW per share.
What do the bullish and bearish scenarios say about 335810?
Our models span a range for Precision Biosensor Inc.: cautious scenario 1,062 KRW, base 1,415 KRW, optimistic 1,769 KRW per share (as of Nov 10, 2026, price 1,355 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Precision Biosensor Inc. (335810)?
Balance-sheet figures for Precision Biosensor Inc. (as of Nov 10, 2026): return on equity −20.2%, debt of 0.05 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is 335810 from its 52-week high?
Precision Biosensor Inc. trades at 1,355 KRW, about 57% below its 52-week high of 3,170 KRW and 14% above the low of 1,190 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 1,415 KRW is for.
Which stocks are comparable to Precision Biosensor Inc.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Precision Biosensor Inc. stock attractive at the current price?
The data as of Nov 10, 2026: price 1,355 KRW, calculated fair value 1,415 KRW (+4%), Quality Score 37/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Precision Biosensor Inc. currently trades 4% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Precision Biosensor Inc. (335810)?
The closing price on Nov 10, 2026 was 1,355 KRW. Our estimate is 1,415 KRW, about +4% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Precision Biosensor Inc. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Precision Biosensor Inc.

How large is the market capitalisation of Precision Biosensor Inc. (335810)?
The market capitalisation of Precision Biosensor Inc. is 29.6B KRW (≈ $22.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Precision Biosensor Inc. (335810)?
The price-to-sales ratio of Precision Biosensor Inc. is 1.33 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Precision Biosensor Inc. (335810)?
Earnings per share at Precision Biosensor Inc. are −290.33 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Precision Biosensor Inc. (335810)?
The net margin of Precision Biosensor Inc. is −26.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Precision Biosensor Inc. (335810)?
The return on equity (ROE) of Precision Biosensor Inc. is −20.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Precision Biosensor Inc. (335810)?
On an EBIT basis the return on assets of Precision Biosensor Inc. is −8.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Precision Biosensor Inc. (335810)?
The operating margin of Precision Biosensor Inc. is −19.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Precision Biosensor Inc. (335810)?
Revenue at Precision Biosensor Inc. is growing +26.9% versus a year earlier (3y avg −0.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Precision Biosensor Inc. (335810) generate?
The free cash flow of Precision Biosensor Inc. is −1.7B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Precision Biosensor Inc. (335810) carry?
The net debt of Precision Biosensor Inc. is 10.1B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Precision Biosensor Inc. in the live analysis

One click puts Precision Biosensor Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.